Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1400 participants.

Also called NCT05679024

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05679024
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Finland, Iceland, Norway, Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05679024. Randomized; no masking; primary purpose treatment. Start 2023-02-17 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Acronym
SACK
Condition
Chronic Kidney Diseases
Condition
Stroke
Condition
Intracerebral Hemorrhage
Condition
Major Bleed
Condition
Cardiovascular Complication
Condition
Death
Condition
Kidney Transplant; Complications
Condition
Thromboses, Venous
Intervention (Drug)
Apixaban 2.5 milligram Oral Tablet
Lead sponsor
Region Stockholm (class: other government)

Record details

Record id
cardio:ct-nct05679024
Content hash
f639a9b2a56a5ff025f50fc936402d5122ea771961ed059153ef0dbfccec5daa